Frans De Baets
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Frans De Baets has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
S. Van Daele
16 shared publications- Petra Schelstraete
Cystic Fibrosis Centre, Ghent University Hospital (GUH), Ghent, Belgium
11 shared publications D. Declercq
10 shared publicationsS. Van Biervliet
10 shared publicationsM. Vaneechoutte
6 shared publicationsF. Haerynck
5 shared publications
Latest Publications
- 1 February 2019
- Published by Elsevier in Clinical Nutrition ESPEN
- Vol. 29, 15-21
The nutritional status in CF: Being certain about the uncertainties
- 1 February 2019
- Published by Elsevier in Clinical Nutrition ESPEN
- Vol. 29, 15-21
The nutritional status in CF: Being certain about the uncertainties
- 7 July 2018
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 29 (7) , 726-731
Risk factors and impact of allergic bronchopulmonary aspergillosis in Pseudomonas aeruginosa‐negative CF patients
Background: Allergic bronchopulmonary aspergillosis (ABPA) is a major complication in cystic fibrosis (CF) patients. Risk factors for ABPA and clinical deterioration in CF patients, negative for Pseudomonas aeruginosa (Pa), were explored.Methods: We performed a retrospective case‐control study in 73 Pa‐negative patients. Each patient was matched with 2 controls for age, gender, pancreas sufficiency, DeltaF508 mutation (homozygous or heterozygous), and Pa colonization.Results: Median FEV1 at the year of diagnosis (index year) was significantly lower in patients with ABPA. The median of cumulative values of FEV1 and FVC before the index year was not significantly different. After the index year, the median of cumulative data for FEV1 and FVC was significantly lower; there were significantly more hospitalization days and more IV antibiotic days compared to controls. Comparing pre‐ and post‐index year data in patients with ABPA, significantly more hospitalization days and more IV antibiotic days were observed after the index year. During the period preceding the index year, significantly more ABPA patients were treated with rhDNase and inhaled corticosteroids.Conclusions: Bronchial damage cannot be considered as a facilitating factor for ABPA. ABPA causes a significant increase in bronchial damage. In patients with ABPA, further bronchial damage can be controlled by an increase in hospitalization days and use of IV antibiotics. rhDNase and inhaled corticosteroids were associated with the development of ABPA.
- 7 July 2018
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 29 (7) , 726-731
Risk factors and impact of allergic bronchopulmonary aspergillosis in Pseudomonas aeruginosa‐negative CF patients
Background: Allergic bronchopulmonary aspergillosis (ABPA) is a major complication in cystic fibrosis (CF) patients. Risk factors for ABPA and clinical deterioration in CF patients, negative for Pseudomonas aeruginosa (Pa), were explored.Methods: We performed a retrospective case‐control study in 73 Pa‐negative patients. Each patient was matched with 2 controls for age, gender, pancreas sufficiency, DeltaF508 mutation (homozygous or heterozygous), and Pa colonization.Results: Median FEV1 at the year of diagnosis (index year) was significantly lower in patients with ABPA. The median of cumulative values of FEV1 and FVC before the index year was not significantly different. After the index year, the median of cumulative data for FEV1 and FVC was significantly lower; there were significantly more hospitalization days and more IV antibiotic days compared to controls. Comparing pre‐ and post‐index year data in patients with ABPA, significantly more hospitalization days and more IV antibiotic days were observed after the index year. During the period preceding the index year, significantly more ABPA patients were treated with rhDNase and inhaled corticosteroids.Conclusions: Bronchial damage cannot be considered as a facilitating factor for ABPA. ABPA causes a significant increase in bronchial damage. In patients with ABPA, further bronchial damage can be controlled by an increase in hospitalization days and use of IV antibiotics. rhDNase and inhaled corticosteroids were associated with the development of ABPA.
- 1 June 2018
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 17, S99
P141 The impact of exacerbations on muscle force, exercise capacity and quality of life in adults with cystic fibrosis
- 1 June 2018
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 17, S99
P141 The impact of exacerbations on muscle force, exercise capacity and quality of life in adults with cystic fibrosis
- 1 June 2018
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 17, S112
P187 Evolution of body composition measured by BIA after the start of tube feeding
- 1 June 2018
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 17, S112
P187 Evolution of body composition measured by BIA after the start of tube feeding
- 1 March 2018
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 17 (2) , 264-270
The effect of enteral tube feeding in cystic fibrosis: A registry based study
- 1 March 2018
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 17 (2) , 264-270
The effect of enteral tube feeding in cystic fibrosis: A registry based study
- 1 June 2017
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 16, S10
WS05.7 Impact of tube feeding (TF) on pulmonary function in children and adults with cystic fibrosis
- 1 June 2017
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 16, S10
WS05.7 Impact of tube feeding (TF) on pulmonary function in children and adults with cystic fibrosis
- 1 June 2017
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 16, S133
280 Single centre long-term experience with tube feeding in children with cystic fibrosis
- 1 June 2017
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 16, S133
280 Single centre long-term experience with tube feeding in children with cystic fibrosis
- 1 June 2017
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 16, S147
330 Characteristics at baseline of tube-fed cystic fibrosis (CF) patients with matched controls: a registry study
- 1 June 2017
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 16, S147
330 Characteristics at baseline of tube-fed cystic fibrosis (CF) patients with matched controls: a registry study
- Open Access
- 24 June 2016
- Published by Springer Nature in BMC Microbiology
- Vol. 16 (1) , 1-13
Epidemic Achromobacter xylosoxidans strain among Belgian cystic fibrosis patients and review of literature
Achromobacter xylosoxidans is increasingly being recognized as an emerging pathogen in cystic fibrosis. Recent severe infections with A. xylosoxidans in some of our cystic fibrosis (CF) patients led to a re-evaluation of the epidemiology of CF-associated A. xylosoxidans infections in two Belgian reference centres (Antwerp and Ghent). Several of these patients also stayed at the Rehabilitation Centre De Haan (RHC). In total, 59 A. xylosoxidans isolates from 31 patients (including 26 CF patients), collected between 2001 and 2014, were studied. We evaluated Matrix Assisted Laser Desorption Ionisation -Time of Flight mass spectrometry (MALDI-TOF) as an alternative for McRAPD typing. Both typing approaches established the presence of a major cluster, comprising isolates, all from 21 CF patients, including from two patients sampled when staying at the RHC a decade ago. This major cluster was the same as the cluster established already a decade ago at the RHC. A minor cluster consisted of 13 isolates from miscellaneous origin. A further seven isolates, including one from a non-CF patient who had stayed recently at the RHC, were singletons. Typing results of both methods were similar, indicating transmission of a single clone of A. xylosoxidans among several CF patients from at least two reference centres. Isolates of the same clone were already observed at the RHC, a decade ago. It is difficult to establish to what extent the RHC is the source of transmission, because the epidemic strain was already present when the first epidemiological study in the RHC was carried out. This study also documents the applicability of MALDI-TOF for typing of strains within the species A. xylosoxidans and the need to use the dynamic cutoff algorithm of the BioNumerics® software for correct clustering of the fingerprints.
- 24 June 2016
- Published by Springer Nature in BMC Microbiology
- Vol. 16 (1) , 1-13
Open AccessEpidemic Achromobacter xylosoxidans strain among Belgian cystic fibrosis patients and review of literature
Achromobacter xylosoxidans is increasingly being recognized as an emerging pathogen in cystic fibrosis. Recent severe infections with A. xylosoxidans in some of our cystic fibrosis (CF) patients led to a re-evaluation of the epidemiology of CF-associated A. xylosoxidans infections in two Belgian reference centres (Antwerp and Ghent). Several of these patients also stayed at the Rehabilitation Centre De Haan (RHC). In total, 59 A. xylosoxidans isolates from 31 patients (including 26 CF patients), collected between 2001 and 2014, were studied. We evaluated Matrix Assisted Laser Desorption Ionisation -Time of Flight mass spectrometry (MALDI-TOF) as an alternative for McRAPD typing. Both typing approaches established the presence of a major cluster, comprising isolates, all from 21 CF patients, including from two patients sampled when staying at the RHC a decade ago. This major cluster was the same as the cluster established already a decade ago at the RHC. A minor cluster consisted of 13 isolates from miscellaneous origin. A further seven isolates, including one from a non-CF patient who had stayed recently at the RHC, were singletons. Typing results of both methods were similar, indicating transmission of a single clone of A. xylosoxidans among several CF patients from at least two reference centres. Isolates of the same clone were already observed at the RHC, a decade ago. It is difficult to establish to what extent the RHC is the source of transmission, because the epidemic strain was already present when the first epidemiological study in the RHC was carried out. This study also documents the applicability of MALDI-TOF for typing of strains within the species A. xylosoxidans and the need to use the dynamic cutoff algorithm of the BioNumerics® software for correct clustering of the fingerprints.